The Regorafenib tablet gains EU approval for the treatment of metastasized colorectal cancer (mCRC) in adults, whose disease has progressed even after treatment with standard drugs. Regorafenib was previously approved by the FDA in late May 2012 to treat patients with metastatic colorectal cancer. That initial approval of Regorafenib for unresectable colon cancer was based on the[…]
Regorafenib Tablet Gains EU Approval for Colorectal Cancer Treatment
Chemotherapeutic / Anti-Neoplastic, EU Approved 2013 Tags: EGFREUregorafenib Sep 03, 2013
Lixisenatide Approved By the EU and Being Reviewed By the FDA
Anti-Diabetic, Drug Research & Development API, EU Approved 2013, NDA Tags: HbA1cNew Drug Applicationtype 2 Diabetes Feb 27, 2013
As a treatment for Type 2 diabetes lixisenatide is approved by the EU and currently under review as a New Drug Application {NDA} by the FDA. Sanofi is preparing to launch lixisenatide in the European Union as in the latter of first quarter 2013, with the proprietary name Lyxumia. What makes lixisenatide unique is not[…]
